Abivax shares surge as ABX-464 shows promise in draining HIV reservoirs

DUBLIN – Shares in Abivax SA surged by more than 175 percent during trading Tuesday on news that its HIV maturation inhibitor, ABX-464, may be able to reduce viral reservoirs in HIV-infected patients who already have undetectable plasma viral load.

Read the article here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here